Ocugen said today that it launched the first of two pivotal Phase III trials for its OCU300 nanoemulsion designed to treat the symptoms of ocular graft versus host disease.
The Malvern, Penn.-based company’s drug is a nanoemulsion formulation of brimonidine tartrate made using Ocugen’s OcuNanoE technology.
Get the full story at our sister site, Drug Delivery Business News.
The post Ocugen launches Ph3 trial for eye disease nanoemulsion appeared first on MassDevice.